Triple Oral Metronomic Chemotherapy (Erlotinib + Methotrexate + Celecoxib) in Head and Neck / Hypopharyngeal Cancer

• Erlotinib 150 mg once daily (EGFR tyrosine kinase inhibitor)
• Celecoxib 200 mg twice daily (COX-2 inhibitor / anti-inflammatory)
• Methotrexate 9 mg/m² weekly (antifolate cytotoxic)

Rationale for the Combination

Evidence Base (Chronological)

1. Preliminary Audit - Malabar Cancer Center (2016) [PMID: 27275445]

• Design: Single-arm prospective observational, n=15 patients, recurrent/metastatic HNSCC
• Regimen: Oral methotrexate 15 mg/m²/week + celecoxib 200 mg BD + erlotinib 150 mg OD
• Results: ORR 60% (2 CR + 7 PR out of 15), median PFS 148 days (~5 months)
• Toxicity: Grade 3-4 adverse events in 40%; dose reduction required in 26.7%
• Conclusion: Combination is feasible with promising PFS; recommended formal testing. Primary sites were predominantly oral cavity (73%), with some hypopharynx/larynx patients included.

2. Phase I/II Study - Tata Memorial Hospital (JCO 2019) [PMID: 31539316]

• Design: Phase I dose-finding + Phase II expansion; n=91 platinum-refractory/early-failure oral/HNSCC patients
• Optimal Biologic Dose (OBD): Methotrexate 9 mg/m²/week identified in Phase I using circulating endothelial cell (CEC) levels as surrogate biomarker
• Phase II results (primary endpoint: 3-month PFS rate):
  • 3-month PFS rate: 71.1% (95% CI, 60.5-79.3%)
  • 6-month OS rate: 61.2% (95% CI, 49.2-67.8%)
  • Response rate (ORR): 42.9% (95% CI, 33.2-53.1%)
  • QoL (FACT-H&N) improved by 6.1 units at day 8 and maintained
• Conclusion: Regimen is efficacious in platinum-refractory HNSCC; established as a new therapeutic option. Note: This study focused on oral cavity SCC; hypopharyngeal cancer patients were not the primary population.

3. Long-Term Outcomes of the Phase I/II Cohort (Lancet Reg Health SE Asia, 2023) [PMID: 37384062]

• Design: Long-term follow-up of the above 91-patient cohort; median follow-up 41 months
• Results:
  • Median OS: 6.7 months (95% CI 5.4-7.4)
  • 1-year OS: 14.1%; 2-year OS: 5.9%
  • Median PFS: 4.3 months
  • Baseline circulating endothelial cells (CECs) independently predicted better OS (HR 0.46, p=0.002) and PFS (HR 0.48, p=0.002)
  • Non-tobacco users had better PFS (HR 0.51, p=0.03)
• Interpretation: Long-term OS remains modest, but this is expected in platinum-refractory disease. CEC level is a useful biomarker for selecting patients likely to benefit.

4. METRO-CHASE Study - Phase III RCT (JCO Global Oncology, 2025) [PMID: 40403198]

• Design: Phase III, randomized, open-label; n=214 platinum-refractory advanced HNSCC
• Arms: Triple OMCT (erlotinib + celecoxib + methotrexate) vs. Chemotherapy of Physician Discretion (CPD)
• Results:

• QoL: OMCT improved global health status, physical function, fatigue, and insomnia vs. CPD
• Significance: This is the first Phase III RCT confirming superiority of Triple OMCT over standard physician-choice chemotherapy in platinum-refractory HNSCC
• Site mix: Included all HNSCC subsites (oral cavity, oropharynx, larynx, hypopharynx)

5. METRO PLUS Study - Phase III RCT (JCO Global Oncology, 2026) [PMID: 42308452]

• Design: Phase III, randomized, open-label superiority trial; n=238 platinum-sensitive unresectable advanced HNSCC (first-line palliative setting)
• Arms: Paclitaxel-Carboplatin (PC) + Triple OMCT vs. PC alone
• Results:

• QoL: Clinically meaningful preservation across multiple domains in the OMCT arm
• Significance: Adding Triple OMCT to carboplatin-paclitaxel nearly doubles OS in first-line palliative HNSCC, with no added significant toxicity. Positions OMCT as a feasible, cost-effective option in resource-limited settings.

Hypopharyngeal Cancer Specifically

• All Phase II/III trials above enrolled all-HNSCC populations including hypopharyngeal patients
• Hypopharyngeal SCC is biologically similar to other HNSCC (high EGFR, COX-2 expression)
• The METRO-CHASE and METRO PLUS trials stratified by tumor site, but site-specific subgroup data for hypopharynx are not fully published
• The ASCO 2025 abstract (e18038) comparing dual vs. triple metronomic therapy confirmed the benefit of adding erlotinib to the dual regimen (methotrexate + celecoxib) with significantly improved OS and PFS

Summary of Evidence Strength

Clinical Considerations

• Dosing: Erlotinib 150 mg OD + Celecoxib 200 mg BD + Methotrexate 9 mg/m²/week (all oral)
• Monitoring: CBC weekly initially (methotrexate myelosuppression); LFTs; skin/GI toxicity from erlotinib
• Patient selection: Consider baseline CEC measurement if available - higher CEC predicts better response
• Access/cost: All three drugs are generic and inexpensive - a key advantage in resource-limited settings where cetuximab or pembrolizumab may be inaccessible
• Limitations: Most data come from Indian centers; oral cavity SCC is over-represented in study populations; hypopharynx-specific efficacy data are limited

METRO-CHASE Trial - Complete Analysis

Background and Rationale

Study Design

Patient Population

• 214 patients with advanced HNSCC who had failed prior platinum-based chemotherapy
• Included all HNSCC subsites: oral cavity, oropharynx, hypopharynx, larynx
• Prior treatment history was identified as a significant prognostic factor for OS (in multivariable analysis)
• Age, tumor site, and prior treatment were significant prognostic factors for PFS

Results

Primary Endpoint - Overall Survival

• A 37% reduction in risk of death with triple OMCT
• Highly statistically significant

Secondary Endpoint - Progression-Free Survival

• 33% reduction in risk of progression or death

Quality of Life

• Global health status
• Physical functioning
• Fatigue
• Insomnia

Safety

Contextual Prognostic Analysis

• OS: Previous treatment history was the only significant independent prognostic factor
• PFS: Age, tumor site, and previous treatment were independent prognostic factors

Significance and Context

1. First Phase III RCT to demonstrate superiority of Triple OMCT over any standard second-line chemotherapy in platinum-refractory HNSCC
2. All-oral, once/twice daily regimen - no IV access, no hospital visits for infusions
3. Cost: All three drugs are generic; combined monthly cost is approximately USD 20-50 in India, compared to USD 5,000-15,000/month for pembrolizumab or cetuximab
4. Global equity: Directly addresses the treatment gap in low- and middle-income countries (LMICs) where immunotherapy and cetuximab are largely inaccessible
5. Better QoL + fewer toxicities despite superior survival - uncommon in oncology trials

Positioning Within the Evidence Ecosystem

Limitations

• Single-country trial (India) - generalizability to Western populations uncertain (different tobacco exposure patterns, HPV prevalence, oral cavity predominance)
• Open-label design - cannot blind allocation in this drug class
• CPD arm included a wide variety of agents, making it a heterogeneous comparator
• Absolute OS values (5 months vs. 3.1 months) remain modest - reflects the dismal biology of platinum-refractory HNSCC
• Subgroup data by tumor site (including hypopharynx specifically) are not separately reported in the abstract
• Long-term follow-up data are still maturing

Bottom Line